Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALDER BIOPHARMACEUTICALS INCALDR · Entity 154258 | Chief Business Officer | June 01, 2018 | June 05, 2018 |
| ALPINE IMMUNE SCIENCES, INC.ALPN · Entity 90802 | See Remarks | February 06, 2019 | February 08, 2019 |
| LeonaBio, Inc.LONA · Entity 1487 | Director · PRESIDENT and CEO | April 09, 2026 | April 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALDER BIOPHARMACEUTICALS INC
Report date June 01, 2018 · Filed June 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,916 |
Reported balance
After 2018-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-01 · Exercise / conversion · Acquired 22,727 · Balance 124,916 F1: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2: Includes 847 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2018. |
| Common StockSEC Table I · non-derivative | Direct | 106,663 |
Reported balance
After 2018-06-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-06-01 · Sale · Disposed 18,253 · Balance 106,663 F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.1750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 102,189 |
Reported balance
After 2018-06-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2018-06-01 · Sale · Disposed 4,474 · Balance 102,189 F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to $18.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2019-04-20 | Direct | 0 |
Reported balance
After 2018-06-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-06-01 · Exercise / conversion · Disposed 22,727 · Balance 0 F6: The shares subject to this stock option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectHeld in trust for the benefit of Reporting Person's minor child | 26,000 |
Reported balance
Holding disclosure · report date 2018-06-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 26,000 |
| Common StockSEC Table I · non-derivative | IndirectHeld in trust for the benefit of Reporting Person's minor child | 26,000 |
Reported balance
Holding disclosure · report date 2018-06-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 26,000 |
| Common StockSEC Table I · non-derivative | IndirectHeld in trust for the benefit of Reporting Person's minor child | 26,000 |
Reported balance
Holding disclosure · report date 2018-06-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 26,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
F2: Includes 847 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2018.
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.1750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to $18.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.
F6: The shares subject to this stock option are fully vested.
ALPINE IMMUNE SCIENCES, INC.
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2028-08-05 | Direct | 25,000 |
Reported balance
After 2019-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-06 · Grant · Acquired 25,000 · Balance 25,000 F2: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F1: On August 6, 2018, the reporting person was granted an Option to purchase 50,000 shares of Common Stock. The shares underlying the Option vest in two equal tranches upon the reporting person's satisfaction of certain performance criteria. On February 6, 2019, the compensation committee of the Issuer's board of directors determined that the performance criteria for one half of the shares underlying the Option were satisfied, resulting in the vesting of 25,000 of the shares of Common Stock underlying the Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51 · Expires 2029-02-05 | Direct | 75,000 |
Reported balance
After 2019-02-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-06 · Grant · Acquired 75,000 · Balance 75,000 F2: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F3: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of February 6, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 6, 2018, the reporting person was granted an Option to purchase 50,000 shares of Common Stock. The shares underlying the Option vest in two equal tranches upon the reporting person's satisfaction of certain performance criteria. On February 6, 2019, the compensation committee of the Issuer's board of directors determined that the performance criteria for one half of the shares underlying the Option were satisfied, resulting in the vesting of 25,000 of the shares of Common Stock underlying the Option.
F2: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F3: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of February 6, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date.
LeonaBio, Inc.
Report date April 09, 2026 · Filed April 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.54 · Expires 2036-04-08 | Direct | 750,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 750,000 · Balance 750,000 F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2018 Filed Jun 5, 2018 17:40 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 18,253 | $17.74 | $323,824.65 |
DisclosureSEC source: 0001209191-18-035863 · doc4.xml · nonDerivative · entry 2 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,663 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.1750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:40 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 22,727 | $0.99 | $22,499.73 |
DisclosureSEC source: 0001209191-18-035863 · doc4.xml · nonDerivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · balance_after: Includes 847 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 17:31 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012036 · doc4.xml · derivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 17:54 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,519 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-17-060971 · doc4.xml · derivative · entry 6 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,519 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 17:54 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 16,519 | $10.80 | $178,486.14 |
DisclosureSEC source: 0001209191-17-060971 · doc4.xml · nonDerivative · entry 2 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,932 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.55 to $11.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 17:54 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 16,519 | $1.65 | $27,256.35 |
DisclosureSEC source: 0001209191-17-060971 · doc4.xml · nonDerivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:20 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,520 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-17-057340 · doc4.xml · derivative · entry 6 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,519 Underlying: Common Stock · 16,520 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:20 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 16,520 | $12.33 | $203,703.16 |
DisclosureSEC source: 0001209191-17-057340 · doc4.xml · nonDerivative · entry 2 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,932 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.15 to $12.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:20 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 16,520 | $1.65 | $27,258.00 |
DisclosureSEC source: 0001209191-17-057340 · doc4.xml · nonDerivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 17:22 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-17-006426 · doc4.xml · derivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 18:38 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,498 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-17-004982 · doc4.xml · derivative · entry 6 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,039 Underlying: Common Stock · 1,498 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 18:38 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 1,498 | $23.10 | $34,598.71 |
DisclosureSEC source: 0001209191-17-004982 · doc4.xml · nonDerivative · entry 2 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,932 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 18:38 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 1,498 | $1.65 | $2,471.70 |
DisclosureSEC source: 0001209191-17-004982 · doc4.xml · nonDerivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. Read SEC document |
| January 09, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · derivative · entry 14 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,537 Underlying: Common Stock · 500 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 09, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 500 | $23.00 | $11,500.00 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · nonDerivative · entry 7 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,932 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. Read SEC document |
| January 09, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 500 | $1.65 | $825.00 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · nonDerivative · entry 6 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,326 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · derivative · entry 13 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,037 Underlying: Common Stock · 1,326 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,474 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · derivative · entry 12 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,474 shares Expires 2017-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 6,800 | $23.02 | $156,519.68 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · nonDerivative · entry 5 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,932 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 1,326 | $1.65 | $2,187.90 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · nonDerivative · entry 4 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 5,474 | $1.27 | $6,924.61 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · nonDerivative · entry 3 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,216 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · derivative · entry 11 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,474 Underlying: Common Stock · 2,216 shares Expires 2017-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,216 | $23.00 | $50,972.21 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · nonDerivative · entry 2 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,932 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 17:49 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 2,216 | $1.27 | $2,803.24 |
DisclosureSEC source: 0001209191-17-003020 · doc4.xml · nonDerivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016. F2 · balance_after: Includes 365 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2016. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 17:51 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,000 | $27.50 | $55,000.00 |
DisclosureSEC source: 0001209191-16-146390 · doc4.xml · nonDerivative · entry 3 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held in trust for the benefit of Reporting Person's minor child Disclosed balance after: 26,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 17:51 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,000 | $27.50 | $55,005.00 |
DisclosureSEC source: 0001209191-16-146390 · doc4.xml · nonDerivative · entry 2 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held in trust for the benefit of Reporting Person's minor child Disclosed balance after: 26,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 17:51 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,000 | $27.50 | $54,992.80 |
DisclosureSEC source: 0001209191-16-146390 · doc4.xml · nonDerivative · entry 1 Litton Mark James · CIK 0001604834 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held in trust for the benefit of Reporting Person's minor child Disclosed balance after: 26,000 F1 · shares: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.